Relmada Therapeutics (NASDAQ: RLMD) reported Q2 EPS of ($0.59), $0.24 better than the analyst estimate of ($0.83). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .

For earnings history and earnings-related data on Relmada Therapeutics (RLMD) click here.